TCBP
TC BioPharm (Holdings) plc [TCBP] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
TCBP Stock Summary
Top 10 Correlated Stocks
TCBP
In the News
TCBP Financial details
Company Rating
-
Market Cap
1.66M
Income
0
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
41
Optionable
No
Shortable
Yes
Earnings
28 Aug 2024
P/E
-0.87
Forward P/E
-
PEG
-
P/S
0.31
P/B
-47.09
P/C
-
P/FCF
-0.08
Quick Ratio
0.72
Current Ratio
0.81
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
0
EPS next Y
-
EPS next Q
-
EPS this Y
-52.48%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-38.38%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-72.85%
SMA50
-92.73%
SMA100
-97.66%
Inst Own
-
Inst Trans
-
ROA
-13%
ROE
17%
ROC
-6.75%
Gross Margin
100%
Oper. Margin
-314%
Profit Margin
-36%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.85-440.0
52W High
-
52W Low
-
RSI
17.11
Rel Volume
0.02
Avg Volume
4.8M
Volume
75.47K
Perf Week
-86.36%
Perf Month
-91.39%
Perf Quarter
-99.83%
Perf Half Y
-99.75%
-
-
-
-
Beta
0.328
-
-
Volatility
0.11%, 0.76%
Prev Close
-4.55%
Price
0.21
Change
-19.23%
Company Profile
- Volume Average 4.8M
- Market Capitalization 1.66M
- Employee 41
- CEO Mr. Bryan L. Kobel
- Headquarters Motherwell,GB
- IPO Date 2022-02-11
-
Website
https://www.tcbiopharm.com 
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
